ENHO and breast cancer: Adropin is an endogenous ligand for GPR19 and adropin-mediated activation of GPR19 stimulates the intracellular MAPK/ERK1/2 signaling pathway, which is essential for the upregulation of E-cadherin and accompanying phenotypic changes in human breast cancer cells (11).